A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

NCT05884398 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

420

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castrate-sensitive Prostate Cancer

Interventions

DRUG: Apalutamide
DRUG: Androgen-deprivation Therapy (ADT)

Sponsor

Janssen Research & Development, LLC